U.S. Stock Market Midday Update: Moderna's stock price soared 8.51%, boosted by vaccine progress and new partnership agreements that enhance market confidence

U.S. Stock Market Midday Update

Moderna rose 8.51%. Based on recent key news:

1. On December 2, Moderna executive Klinger Shannon Thyme submitted Form 4 to the U.S. Securities and Exchange Commission, disclosing changes in shareholding. This move may be interpreted by the market as internal confidence in the company's future development, driving the stock price up.

2. Recently, Moderna has made positive progress in vaccine development, enhancing market expectations for its new products, further stimulating the rise in stock prices.

3. On December 1, Moderna announced new cooperation agreements with several international institutions, expanding its market influence and boosting investor confidence. The demand in the vaccine industry is strong, with significant capital inflow.

Stocks with High Trading Volume in the Industry

Praxis Precision Medicines rose 30.29%. Based on recent key news:

1. On December 5, Praxis Precision Medicines announced that its tremor drug ulixacaltamide's New Drug Application (NDA) has been approved by the U.S. FDA. This news propelled the stock price up 36%, reaching its highest point in nearly four years. The company also reported positive mid-term results for its rare epilepsy treatment drug relutrigine, with peak sales expected to exceed $2.5 billion. Source: Reuters

2. On December 5, the company decided to terminate an epilepsy study early due to its significant efficacy. This move caused the stock price to soar 30%, reaching a three-year high. Source: CNBC

3. On December 5, Needham maintained a Buy rating on Praxis and raised the target price to $304. This rating is based on positive mid-term results from the EMBOLD study, which showed strong efficacy signals supporting the NDA submission. Source: MarketWatch The biopharmaceutical industry has recently performed strongly, with significant capital inflow.

Precision Sciences had a trading volume of $489 million, with increased trading volume and no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

Amgen fell 2.57%. Based on recent key news:

1. On December 4, BMO Capital raised Amgen's target price from $335 to $372, maintaining an "Outperform" rating. This reflects analysts' continued confidence in the biotechnology industry; however, the stock price failed to reflect this positive change, possibly due to market concerns over drug pricing pressures. (Gelonghui)

2. On December 3, Goldman Sachs reiterated its Buy rating on Amgen and set a target price of $400, expecting key trial data for its obesity drug MariTide to drive long-term growth. Nevertheless, market uncertainty regarding the IRS lawsuit remains a concern, affecting stock performance (Zhitong Finance)

On December 4th, Amgen reported third-quarter results that exceeded expectations, primarily driven by sales growth of Repatha and strong contributions from Prolia and rare disease drugs. Investors are optimistic about updates on the obesity candidate drug MariTide and the lung cancer therapy Imdelltra, but drug pricing pressure remains a focal point for the market. (Wall Street Watch) The biotechnology industry is facing drug pricing pressure.

Stocks Ranked Among the Top by Market Capitalization in the Industry

AbbVie fell 0.94%. Based on recent key news:

1. On December 5th, AbbVie's immunology business continued to perform strongly after losing patent protection for Humira, primarily driven by Skyrizi and Rinvoq. Sales of these two drugs increased by 53% year-on-year, reaching $18.5 billion, and are expected to exceed $31 billion by 2027. This growth provides the company with a stable source of income, despite competitive pressure from Johnson & Johnson and Eli Lilly.

2. On December 5th, AbbVie emphasized the necessity of new treatment strategies for platinum-resistant ovarian cancer at the ESMO Asia 2025 conference. Experts discussed the potential of antibody-drug conjugates (ADCs) to improve efficacy and patient quality of life, indicating the company's innovative efforts in cancer treatment.

3. On December 5th, analyst ratings show that AbbVie is currently rated as "Moderate Buy," but it has not been included in the list of the top five stocks recommended by leading analysts. This may affect investor confidence, leading to a decline in stock prices. Competition in the immunology market is intensifying, with a focus on innovation